Display options
Cite
Bonetta A, Roviello G, Generali D, et al. Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. Res Rep Urol. 2017;9:65-69doi: 10.2147/RRU.S133538.
Bonetta, A., Roviello, G., Generali, D., Zanotti, L., Cappelletti, M. R., Pacifico, C., & Di Pierro, F. (2017). Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. Research and reports in urology, 965-69. https://doi.org/10.2147/RRU.S133538
Bonetta, Alberto, et al. "Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma." Research and reports in urology vol. 9 (2017): 65-69. doi: https://doi.org/10.2147/RRU.S133538
Bonetta A, Roviello G, Generali D, Zanotti L, Cappelletti MR, Pacifico C, Di Pierro F. Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. Res Rep Urol. 2017 Apr 26;9:65-69. doi: 10.2147/RRU.S133538. eCollection 2017. PMID: 28491861; PMCID: PMC5414750.
Copy Download .nbib Format: NLM
Share it on

Res Rep Urol. 2017 Apr 26;9:65-69. doi: 10.2147/RRU.S133538. eCollection 2017.

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma.

Research and reports in urology

Alberto Bonetta, Giandomenico Roviello, Daniele Generali, Laura Zanotti, Maria Rosa Cappelletti, Chiara Pacifico, Francesco Di Pierro

Affiliations

  1. Oncological Radiotherapy Operative Unit, ASST, Cremona.
  2. Department of Molecular and Translational Medicine, University of Brescia, Brescia.
  3. Molecular Therapy and Pharmacogenomics Unit, ASST, Cremona.
  4. Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste.
  5. Department of Medical, Surgical and Neurological Sciences, University Hospital of Siena, Siena.
  6. Velleja Research Scientific Department, Milan, Italy.

PMID: 28491861 PMCID: PMC5414750 DOI: 10.2147/RRU.S133538

Abstract

INTRODUCTION: Worldwide, bacterial resistance to antibiotic therapy is a major concern for the medical community. Antibiotic resistance mainly affects Gram-negative bacteria that are an important cause of lower urinary tract infections (LUTIs). Pelvic irradiation for prostate cancer is a risk factor for LUTIs. Cranberry extract is reported to reduce the incidence of LUTIs. The prophylactic role of an enteric-coated, highly standardized cranberry extract (VO370

METHODS: A total of 924 patients with prostate carcinoma treated by radiotherapy to the prostatic and pelvic areas were randomized to receive (n=489) or not (n=435) the enteric-coated, highly standardized cranberry extract for 6-7 weeks concurrently with irradiation. Outcomes were analyzed by using Mann-Whitney

RESULTS: The treatment was very well tolerated, and there were no serious side effects. All enrolled patients completed the study. Urinary infections were detected in 53 of the 489 patients (10.8%) treated with enteric-coated, highly standardized cranberry extract, while 107 of the 435 patients (24.6%) in the control group developed LUTIs (

CONCLUSION: The enteric-coated, highly standardized cranberry extract could be used as a prophylactic to reduce the incidence of LUTIs and decrease antibiotic therapy in patients receiving pelvic irradiation for prostate cancer.

Keywords: E. coli; PAC-A; UTI; Vaccinium macrocarpon; antibiotic-resistance; botanicals

Conflict of interest statement

Disclosure F Di Pierro belongs to the Scientific Committee of one of the companies trading the tested product. He has the full control of all primary data and agrees to allow the journal to review the

References

  1. Cochrane Database Syst Rev. 2012 Oct 17;10:CD001321 - PubMed
  2. J Med Food. 2009 Apr;12(2):259-70 - PubMed
  3. Urologia. 2015 Oct;82 Suppl 3:S2-5 - PubMed
  4. Infect Dis Clin North Am. 1997 Sep;11(3):551-81 - PubMed
  5. Radiother Oncol. 1989 Dec;16(4):305-9 - PubMed
  6. Clin Oncol (R Coll Radiol). 1990 Jan;2(1):18-21 - PubMed
  7. Molecules. 2016 Jul 05;21(7): - PubMed
  8. Cancer Manag Res. 2012;4:281-6 - PubMed
  9. J Neurosurg. 2011 Aug;115(2):220-9 - PubMed
  10. Expert Rev Anti Infect Ther. 2016 Aug;14(8):747-63 - PubMed
  11. Urology. 1998 Nov;52(5):863-5 - PubMed
  12. Int J Gynecol Cancer. 2016 Apr 21;: - PubMed
  13. J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S175-80 - PubMed
  14. Urol Clin North Am. 1999 Nov;26(4):729-35, viii - PubMed
  15. Crit Rev Food Sci Nutr. 2009 Oct;49(9):741-81 - PubMed
  16. Gynecol Oncol. 1995 Jun;57(3):380-2 - PubMed
  17. Clin Oncol (R Coll Radiol). 1994;6(2):116-20 - PubMed

Publication Types